Evolutionary Genomics, Inc.: 10-Q filed 2022-05-16

Name: Evolutionary Genomics, Inc.: 10-Q filed 2022-05-16
Creator: Evolutionary Genomics, Inc.

What Evolutionary Genomics, Inc. reported in its quarterly report filed 2022-05-16 (fiscal Q1 2022): 33 published measures, 69 facts as tagged in accession 0001553350-22-000464.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-05-16
Fiscal period: fiscal Q1 2022
Accession: 0001553350-22-000464 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Evolutionary Genomics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-03-31	3,504,970	USD
At 2021-12-31	2,932,091	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-03-31	3,762,754	USD
At 2021-12-31	3,762,613	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-03-31	-4,318,522	USD
At 2021-12-31	-4,400,116	USD
At 2021-03-31	-2,284,702	USD
At 2020-12-31	-1,825,890	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-03-31	1,042,290	USD
At 2021-12-31	214,009	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-524,865	USD	90
2021-01-01 to 2021-03-31	-513,742	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-175,723	USD	90
2021-01-01 to 2021-03-31	-194,673	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	1,004,004	USD	90
2021-01-01 to 2021-03-31	76,395	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	0	USD	90
2021-01-01 to 2021-03-31	0	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-03-31	-18,402,361	USD
At 2021-12-31	-17,877,496	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	5,890,046	shares	90
2021-01-01 to 2021-03-31	5,881,898	shares	90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	5,890,046	shares	90
2021-01-01 to 2021-03-31	5,881,898	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-0.1	USD/shares	90
2021-01-01 to 2021-03-31	-0.1	USD/shares	90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-0.1	USD/shares	90
2021-01-01 to 2021-03-31	-0.1	USD/shares	90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-03-31	15,013	USD
At 2021-12-31	18,698	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	56,459	USD	90
2021-01-01 to 2021-03-31	54,930	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-524,944	USD	90
2021-01-01 to 2021-03-31	-513,850	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-03-31	1,084,052	USD
At 2021-12-31	255,801	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-03-31	56,147	USD
At 2021-12-31	18,866	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2022-03-31	2,405,905	USD
At 2021-12-31	2,657,592	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	524,944	USD	90
2021-01-01 to 2021-03-31	513,850	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	99,089	USD	90
2021-01-01 to 2021-03-31	96,815	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-03-31	6,615,231	shares
At 2021-12-31	5,881,898	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-03-31	1,042,290	USD
At 2021-12-31	214,009	USD
At 2021-03-31	97,558	USD
At 2020-12-31	215,836	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2022-03-31	503,665	USD
At 2021-12-31	503,665	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2022-03-31	488,652	USD
At 2021-12-31	484,967	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-524,865	USD	90
2021-01-01 to 2021-03-31	-513,742	USD	90

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-524,865	USD	90
2021-01-01 to 2021-03-31	-513,742	USD	90

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-595,640	USD	90
2021-01-01 to 2021-03-31	-585,134	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	331,896	USD	90
2021-01-01 to 2021-03-31	324,605	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	3,685	USD	90
2021-01-01 to 2021-03-31	8,016	USD	90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	255,372	USD	90
2021-01-01 to 2021-03-31	259,703	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	79	USD	90
2021-01-01 to 2021-03-31	108	USD	90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	550,000	USD	90

Inspect the source

Entity: Evolutionary Genomics, Inc. / CIK 0000884363
Captured: 2026-09-22 19:32 UTC
SEC response SHA-256: a2b66772c1d0ab2271c82d2191d0de1fc92fc9df77b277aa7e747ea7abf31177

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000884363.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))